[Comment] Long-term forgetting in preclinical Alzheimer's disease

Alzheimer's disease is characterised by progressive pathophysiological changes that correspond roughly to preclinical (ie, cognitively unimpaired), mild cognitive impairment, and dementia stages.1 Biomarkers continue to be developed, tested, and used to detect and track the pathophysiological manifestations of this disease. Although neuropsychological tests, clinical ratings, and composite cognitive test scores have shown initial promise,2 –5 the field would benefit from additional ways to detect and track cognitive, behavioural, and functional manifestations of Alzheimer's disease with optimal power, ease, and availability, particularly in the preclinical and early clinical stages.

Source: Lancet Neurology - January 18, 2018 Category: Neurology Authors: Eric M Reiman Tags: Comment Source Type: research